Vivosim Labs, Inc. key statistics and ratios

In fiscal 2026, Vivosim Labs, Inc. had an operating margin of -8768.7% and a current ratio of 2.38. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Vivosim Labs, Inc.: financial ratios, annual
Fiscal year	2011Dec 2010	2012Dec 2011	2013Dec 2012	2014Mar 2014	2015Mar 2015	2016Mar 2016	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026	LTMJun 2026
Gross margin	—	—	—	—	100.0%	100.0%	77.4%	78.3%	83.8%	86.3%	—	—	—	—	96.5%	100.0%	—
Operating margin	−195.4%	−237.9%	−778.5%	<−999%	<−999%	<−999%	−911.9%	−766.3%	−882.4%	−977.9%	—	−765.3%	<−999%	<−999%	<−999%	<−999%	<−999%
Net margin	−222.1%	−452.3%	<−999%	<−999%	<−999%	<−999%	−908.9%	−756.1%	−861.7%	−852.0%	—	−763.2%	<−999%	<−999%	<−999%	<−999%	<−999%
Free-cash-flow margin	−143.9%	−202.3%	−839.6%	<−999%	<−999%	<−999%	−722.0%	−631.8%	−661.7%	−677.7%	—	−590.8%	<−999%	<−999%	<−999%	<−999%	<−999%
Return on equity	—	—	—	−120.3%	−62.0%	−69.6%	−61.7%	−65.1%	−65.9%	−59.5%	−51.1%	−33.0%	−75.8%	−155.0%	−35.3%	—	—
Return on assets	—	−311.1%	−479.7%	−77.2%	−58.0%	−63.7%	−56.2%	−58.5%	−58.9%	−54.2%	−49.2%	−31.3%	−64.4%	−110.1%	−23.7%	−125.6%	−219.7%
Asset turnover	—	0.69	0.13	0.01	0.01	0.02	0.06	0.08	0.07	0.06	—	0.04	0.01	0.01	0.01	0.01	0.02
Current ratio	—	0.52	0.72	25.97	10.77	14.18	10.83	10.04	10.32	15.65	53.26	21.35	4.64	2.12	3.25	2.38	1.70
Debt to equity	—	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	—	—	—	—	—	—	—	—	—	n/m	n/m	n/m
R&D as % of revenue	199.5%	146.5%	287.1%	>999%	>999%	>999%	462.1%	390.1%	477.3%	240.6%	—	221.3%	>999%	>999%	>999%	>999%	>999%
SG&A as % of revenue	95.9%	178.8%	591.5%	>999%	>999%	>999%	527.3%	453.8%	489.5%	822.4%	—	643.9%	>999%	>999%	>999%	>999%	>999%
Capital spending as % of revenue	8.0%	4.7%	29.8%	73.1%	265.7%	142.5%	32.0%	4.9%	2.6%	0.0%	—	27.3%	107.0%	38.5%	9.0%	0.0%	20.5%

US$ thousands unless shown otherwise. Fiscal quarters.

Vivosim Labs, Inc.: financial ratios, quarterly
Quarter	2025 Q2Sept 2024	2025 Q3Dec 2024	2025 Q4Mar 2025	2026 Q1Jun 2025	2026 Q2Sept 2025	2026 Q3Dec 2025	2026 Q4Mar 2026	2027 Q1Jun 2026
Gross margin	96.7%	91.7%	100.0%	100.0%	100.0%	100.0%	100.0%	—
Operating margin	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%
Net margin	<−999%	<−999%	>999%	<−999%	<−999%	<−999%	<−999%	<−999%
Free-cash-flow margin	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%
Current ratio	1.98	0.71	3.25	4.52	3.10	2.44	2.38	1.70
R&D as % of revenue	>999%	>999%	>999%	>999%	>999%	>999%	>999%	>999%
SG&A as % of revenue	>999%	>999%	>999%	>999%	>999%	>999%	>999%	>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026

What it owns · $4m

Short-term assets $3mLonger-term assets $1m

What it owes, and who funded it · $6m

Short-term liabilities $2mLonger-term liabilities $4mShareholders' equity $-2m

Short-term assets cover short-term liabilities $3m of assets due within a year against $2m of liabilities due within a year.
Short-term assets cover long-term liabilities $3m short-term assets against $4m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$11m against $12,000 of interest.

From Vivosim Labs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

18 /100

Weak moat

How hard Vivosim Labs's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Cash operating profit has been a median -38.1% of total assets over 7 years.
Pricing power 14 / 20

Gross margin has been a median 82.5%, moving by 8.5 percentage points (standard deviation) across 6 years.
Durability 10 / 20

Operating margin has been a median -2046.1%; its worst year was -19557.5%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -2240.7% of revenue.
Discipline 0 / 20

The diluted share count rose 558.7% over five years; stock-based pay has been a median 229.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IBIO vs VIVS LSTA vs VIVS AIM vs VIVS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vivosim Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivosim Labs, Inc.